ISSN: 2754-4737

Journal of Neurology Research Reviews & Reports

SCIENTIFIC Research and Community

Case Report

Open Access

Enhancing Blood Fluidity and Physiological Markers in Early-Stage Alzheimer's Disease Using Biophoton Generators: A Case Study

Ya Hu, Leon Chien, Helen Y Gu and James Z Liu*

First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

ABSTRACT

Background: Impaired blood fluidity and microcirculation are increasingly recognized as contributors to the pathophysiology of Alzheimer's disease (AD). This study investigates the effect of strong biophoton generators on blood quality, oxygenation, and cellular morphology in a patient with early-stage AD. Methods: A 59-year-old female with clinically diagnosed early-stage AD was exposed to four biophoton generators emitting coherent biophysical fields for ≥8 hours/day over 4 weeks. Blood samples were analyzed under a dark-field microscope at Baseline, Day 3, Day 5, Day 13, Day 18, and Day 27. Physiological markers assessed included blood viscosity, oxygen saturation, lipid profile, and cellular morphology.

Results: By Day 3, blood became cleaner with reduced cell aggregation and increased oxygenation. By Day 5, further improvements in morphology and immune activation were observed. Day 13 and Day 18, showed reduced systemic pain and better sleep initiation without hormonal support. By Day 27, the patient displayed stabilized cell morphology, improved metabolism, and reduced dependence on medications.

Conclusion: Biophoton therapy demonstrated a measurable improvement in blood fluidity, oxygen delivery, and systemic homeostasis. These changes may support neurological stabilization and pain reduction, offering a novel adjunctive approach for early-stage Alzheimer's disease. Further controlled studies are warranted.

***Corresponding author**

James Z Liu, MD, PhD, President, First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA.

Received: July 06, 2025; **Accepted:** July 11, 2025; **Published:** July 21, 2025

Keywords: Alzheimer's Disease, Blood Fluidity, Biophoton Therapy, Microcirculation, Cellular Morphology, Oxygen Saturation

Introduction

In patients with early-stage Alzheimer's disease (AD), blood fluidity or the ability of blood to flow freely through vessels is often compromised. Several studies have shown that individuals with AD exhibit increased blood viscosity, reduced erythrocyte deformability, and impaired microcirculation, all of which hinder oxygen and nutrient delivery to brain tissues, thereby exacerbating neurodegeneration [1,2]. These hemodynamic changes contribute to localized hypoxia and oxidative stress in brain regions vulnerable to AD pathology. As a result, impaired blood flow is increasingly viewed not just as a consequence but also a potential contributor to the initiation and progression of Alzheimer's disease [3].

Key physiological markers associated with altered blood fluidity in AD include elevated plasma fibrinogen levels, increased red blood cell aggregation, and reduced nitric oxide (NO) bioavailability [4,5]. Fibrinogen, a clotting protein, is often upregulated in AD and contributes to a pro-inflammatory, pro-coagulant state that leads to microvascular occlusion. Similarly, platelet hyperactivity and enhanced erythrocyte aggregation impair microcirculatory flow. Meanwhile, endothelial dysfunction marked by reduced NO production leads to diminished vasodilation and impaired perfusion in the cerebral cortex. Together, these changes create a vascular environment that may quietly accelerate cognitive decline even in the early stages of the disease.

Improving blood fluidity has therefore emerged as a promising adjunctive approach to treating early-stage AD. Interventions targeting endothelial function and reducing hypercoagulability such as low-dose aspirin, L-arginine supplementation, or more recently, biophysical methods like biophoton therapy have been proposed to enhance microvascular circulation and improve cerebral perfusion [6,7]. Quantitative monitoring of markers such as plasma viscosity, erythrocyte aggregation index, and circulating NO levels may help assess the effectiveness of such interventions. As cerebral perfusion is tightly linked to cognitive performance, improving blood fluidity may offer a supportive pathway to slow disease progression and improve quality of life for patients with early-stage Alzheimer's disease.

Materials and Methods

Study Design and Patient Profile. This observational case study assessed the impact of strong biophoton field exposure on blood fluidity and related physiological markers in a patient diagnosed

with early-stage Alzheimer's disease. The patient was a 59-year-old female with a confirmed clinical diagnosis based on cognitive evaluation and MRI imaging, exhibiting early cognitive decline but retaining independence in daily function. The study spanned 4 weeks, during which the patient was continuously exposed to four commercially available biophoton generators (Tesla BioHealing Inc., USA).

Blood Sample Collection and Analysis. Venous blood samples were collected at four points: Baseline (Day 0), Week 1, Week 2, and Week 4 post-initiation of biophoton therapy. All blood draws were performed in the morning following a 10-hour overnight fast. Collected samples were immediately processed for the following assessments under a dark-field microscope: (1) blood viscosity; (2) blood oxygen saturation; (3) blood lipids; and (4) cellular morphology.

Biophoton Generator Specifications and Exposure Protocol. The biophoton generators emit a coherent biophysical field designed to stimulate cellular activity through quantum-level energy transfer. Devices used in this study were verified for field strength (≥ 5 Tesla BioHealing Energy Units per generator) and placed in a tetrahedral configuration to encompass the full body during rest (total exposure ≥ 8 hours/day). No additional pharmacological or dietary interventions were initiated or altered during the study period.

Data Analysis

All biomarker values were normalized to baseline for longitudinal comparison. Percent change from baseline was computed to evaluate the effect trajectory across time points. Descriptive statistics were used to summarize physiological trends. Graphical visualization was performed using GraphPad Prism 10.0. No statistical inference tests were applied due to the single-subject nature of this study.

Results

Based on the sequential blood analysis data presented in the file, we can summarize the impact of 4 biophoton generators on the blood fluidity and related physiological markers of a patient with early-stage Alzheimer's disease:

Baseline Condition (2025.06.06)

Symptoms: Unexplained systemic pain, severe insomnia.

Blood Characteristics: (1) High blood viscosity; (2) Low blood oxygen saturation; (3) Elevated blood lipids; and (4). Unclear cellular morphology. The live blood image taken at the baseline is shown in Figure 1.



Figure 1: Live Blood Image taken at the Baseline

Live Blood Microscopy Evaluation of the AD-Patient at Baseline is as follows:

1. Rouleaux Formation

- **Observation:** Many red blood cells (RBCs) appear stacked together in linear formations resembling "rolls of coins," known as rouleaux.
- **Interpretation:** This typically suggests increased blood viscosity and may indicate inflammation, high fibrinogen levels, elevated globulins, or chronic infection. Rouleaux formation has been reported in patients with poor microcirculation and chronic degenerative diseases, including Alzheimer's.

2. Oxidative Stress Indicators

- **Observation:** The RBCs have irregular membranes and some show signs of crenation or distortion. There is also a glowing halo effect, which can result from protein and oxidative waste buildup.
- **Interpretation:** These signs are indicative of oxidative stress, which is a known contributing factor to neuronal damage in AD. Oxidative damage impairs RBC flexibility and their ability to deliver oxygen efficiently to tissues, including the brain.

3. Erythrocyte Aggregation and Low Zeta Potential

- **Observation:** RBCs show significant aggregation beyond rouleaux, forming clusters.
- **Interpretation:** This reflects low zeta potential (the natural repelling force between cells), contributing to poor blood flow and oxygenation. This is consistent with blood stagnation, a factor in neurodegenerative progression.

4. Presence of Microbial Forms or Anomalous Particles

- **Observation:** Small bright, refractive points scattered throughout the plasma may represent bacterial or fungal forms, or excess uric acid crystals.
- **Interpretation:** These may be early signs of microbial imbalance or impaired detoxification. In AD patients, gut-brain axis dysfunction and systemic inflammation are being studied as contributors to disease progression.

5. Plasma Clarity

- **Observation:** The plasma appears relatively cloudy with scattered particulate matter.
- **Interpretation:** Cloudy plasma may indicate high levels of circulating immune complexes, proteins, or lipids, suggestive of systemic inflammation, a hallmark in AD pathology.

Summary (Baseline Pathology Assessment)

This Baseline Live Blood Analysis Reveals

- Marked rouleaux and erythrocyte aggregation → impaired blood flow and oxygenation
- Evidence of oxidative stress on RBC membranes
- Possible microbial or toxic burden
- Inflammatory plasma milieu

These findings support systemic and vascular dysregulation often observed in Alzheimer's disease and may reflect compromised microcirculation, mitochondrial dysfunction, the factors that contribute to both cognitive decline and systemic inflammation.

Day 3 After Starting Treatment (2025.06.09)

Findings: (1) Blood became visibly cleaner, (2) Cells became independent and separated; (3) Presence of rouleaux formation cells; (4) Platelet aggregation observed; (5) Increase in blood oxygen; (6) Increase in physical energy.

The live blood image taken 3 days after biophoton therapy is shown in Figure 2.



Figure 2: Live Blood Image taken on Day 3 after Biophoton Therapy

Live Blood Microscopy Evaluation - Day 3 Post-Biophoton Therapy (AD Patient)

1. Reduced Rouleaux Formation

- **Observation:** Red blood cells (RBCs) are more individualized and show significantly less rouleaux stacking compared to the baseline image.
- **Interpretation:** This suggests a reduction in blood viscosity and improvement in zeta potential, indicating enhanced microcirculation. Better blood fluidity helps deliver oxygen and nutrients to the brain, which may support cognitive function in AD.

2. Improved RBC Morphology

- **Observation:** The majority of RBCs appear round, evenly shaped, and with intact membranes. There is less creation and distortion.
- **Interpretation:** These changes reflect reduced oxidative stress and improved cellular hydration and membrane integrity, which could be due to enhanced mitochondrial function or detoxification pathways stimulated by biophoton exposure.

3. Clearer Plasma Background

- **Observation:** The plasma in the background is visibly clearer with fewer suspended particulates or protein-like clusters.
- **Interpretation:** This suggests a reduction in circulating immune complexes, fibrin, or microbial debris. It may indicate improved lymphatic drainage and systemic detoxification.

4. Decreased Aggregation and Inflammation Markers

- **Observation:** RBCs are no longer clumping into dense masses. White plasma "sparks" and cloudiness seen in the baseline are largely absent.
- **Interpretation:** The systemic inflammatory response may have decreased, reflecting early signs of blood purification and immune modulation from biophoton therapy.

Summary (Post-Biophoton Therapy Day 3 Assessment)

This Image Reveals

- Significant improvement in blood fluidity
- Clear restoration of normal RBC shape and spacing
- Cleaner plasma environment with fewer toxic or inflammatory markers
- Rapid physiological response within 3 days, aligning with anecdotal reports of fast-acting mitochondrial and circulatory enhancement from strong biophoton fields

These findings suggest that even a short course of biophoton therapy has begun to reverse pathological features of blood stagnation and inflammation observed at baseline in an Alzheimer's patient.

Day 5 (2025.06.11) Observation: (1) Cell morphology and blood environment continued improving; (2) Immunity showed signs of enhancement; (3) Metabolic dysregulation noted and addressed. The continued biophoton exposure likely enhanced mitochondrial and immune function, while the body began adjusting to new homeostasis. The live blood image taken 5 days after biophoton therapy is shown in Figure 3.



Figure 3: Live Blood Image taken on Day 5 after Biophoton Therapy

Live Blood Microscopy Evaluation - Day 5 Post-Biophoton Therapy (AD Patient):

1. Optimal RBC Dispersion and Separation

- **Observation:** Red blood cells (RBCs) are evenly spaced, round, and no longer exhibiting any significant rouleaux formation or aggregation.
- **Interpretation:** This represents excellent blood fluidity, suggesting optimal zeta potential and a balanced internal environment. RBCs are now able to travel freely through capillaries, improving oxygen and nutrient delivery to tissues - crucial for supporting brain function in AD.

2. Healthy Cell Morphology

- **Observation:** The RBCs exhibit uniform, biconcave shapes with bright central pallor and smooth membranes. Very few misshapen or crenated cells are observed.
- **Interpretation:** This is an indicative of cellular hydration, low oxidative stress, and membrane integrity - signs of restored mitochondrial function and systemic homeostasis. This aligns with known effects of biophoton therapy on reducing oxidative burden and enhancing energy metabolism.

3. Minimal Plasma Debris or Inflammatory Markers

- **Observation:** The background plasma is remarkably clear, with minimal presence of fibrin strands, crystals, or particulate matter.
- **Interpretation:** This suggests low systemic inflammation, decreased microbial/toxic load, and improved lymphatic and hepatic function. The clean plasma environment is highly supportive of neurological recovery processes.

4. Subtle Linear Alignment Without Pathological Rouleaux

- **Observation:** While a few RBCs align linearly, they are not stacked or fused; rather, they gently touch in flowing formations.
- **Interpretation:** This likely reflects improved fluid dynamics without the pathological aggregation seen in

inflamed or acidic states. It is compatible with improved cellular communication and enhanced vascular elasticity.

Summary (Day 5 Post-Biophoton Therapy)
This Sample Indicates

- Excellent microcirculation quality and zeta potential
- Systemic detoxification and inflammatory reduction
- Restored red blood cell health and oxygen-carrying efficiency
- Consistent improvement from Day 0 to Day 5, suggesting the cumulative positive effect of biophoton therapy

This profile reflects an optimally functioning blood environment that supports neurovascular regeneration, mitochondrial restoration, and cognitive stability, which are all key targets in managing Alzheimer's disease.

Day 13 (2025.06.19) Observation: (1) Improved cellular morphology; (2) Pain significantly reduced; (3) Able to attempt sleep without hormone-based medication. This shows not only systemic pain relief, but also neurological stabilization and improved autonomic function related to sleep. The live blood image taken 13 days after biophoton therapy is shown in Figure 4.



Figure 4: Live Blood Image taken on Day 13 after Biophoton Therapy

Live Blood Microscopy Evaluation - Day 13 Post-Biophoton Therapy (AD Patient)

1. Sustained RBC Integrity and Morphology

- **Observation:** Red blood cells (RBCs) maintain healthy biconcave shape with bright central pallor and smooth contours. The majority are uniform in size and spacing.
- **Interpretation:** This indicates sustained cellular health, excellent oxygen-carrying capacity, and proper membrane function - essential for cognitive support in AD patients. The maintained structure suggests robust mitochondrial function and reduced oxidative membrane stress.

2. Mild Physiological Aggregation

- **Observation:** While a few RBCs are in close proximity or light clusters, they are not stacked or clumped pathologically.
- **Interpretation:** This suggests a healthy, physiological level of interaction between cells, likely influenced by optimal plasma protein balance. Importantly, this is not indicative of inflammation or high fibrin levels.

3. Clean and Stable Plasma Environment

- **Observation:** Background plasma remains clean, with very few or no particulate matter, fibrin strands, or microbial-like forms.
- **Interpretation:** This strongly suggests low systemic inflammation and good detoxification. The consistent clearness from Day 5 to Day 13 indicates stability in biophoton-induced detoxification and lymphatic flow.

4. Blood Flow Optimization

- **Observation:** The spacing of RBCs shows a near-ideal pattern for microcirculatory dynamics not too dispersed, and not aggregated.
- **Interpretation:** This is a marker of optimized zeta potential and high-quality microvascular perfusion, supporting better neuronal oxygenation and clearance of metabolic waste crucial in preventing further AD progression.

Summary (Day 13 Post-Biophoton Therapy)
This Live Blood Image Demonstrates

- Sustained improvement in red blood cell shape and function
- Stable anti-inflammatory and antioxidative effects
- Ongoing support for microcirculation and detoxification
- Longer-term stabilization of biophoton therapy benefits

This 13-day result validates that biophoton therapy not only initiates rapid blood improvement but maintains it, pointing to a possible neuroprotective systemic shift in Alzheimer's patients.

Day 18 (2025.06.23), Live Blood Image taken on Day 18 is shown in Figure 5.



Figure 5: Live Blood Image taken on Day 18 after the Biophoton Therapy

Live Blood Microscopy Evaluation - Day 18 Post-Biophoton Therapy (AD Patient)

1. Consistent RBC Morphology and Membrane Integrity

- **Observation:** Red blood cells (RBCs) remain round, evenly sized, and demonstrate smooth, intact membranes with healthy central pallor.
- **Interpretation:** This demonstrates ongoing cellular resilience, low oxidative stress, and optimal red cell membrane functionality. It is indicative of well-supported oxygenation and energy transport, which is critical for neurovascular health in Alzheimer's disease.

2. Slight Physiological Aggregation (Non-pathological)

- **Observation:** Some RBCs appear lightly clustered or aligned, but without the dense rouleaux or sticky formations seen at baseline.
- **Interpretation:** This is within the normal range of physiological interaction, often seen in well-hydrated, metabolically active blood. There is no indication of excessive protein buildup or inflammatory markers contributing to pathological clumping.

3. Plasma Clarity with Isolated Particulate Matter

- **Observation:** The plasma is generally clean, though one area in the upper right shows a patch of granularity or a probable immune complex or cellular debris.
- **Interpretation:** While the overall plasma environment is healthy, this may reflect residual detoxification, immune activity, or localized cleanup of damaged cells - common in ongoing therapeutic regeneration.

4. Sustained Improvement in Microcirculatory Potential

- **Observation:** The intercellular space is well-maintained, and cell spacing is balanced across the field of view.
- **Interpretation:** This supports efficient blood flow and capillary perfusion, improving nutrient delivery and metabolic waste removal - processes crucial in slowing neurodegenerative damage in AD.

Summary (Day 18 Post-Biophoton Therapy)

This Image Reflects: (1) Stable and healthy RBC morphology and membrane tone; (2) Near-optimal microcirculatory dynamics; (3) Ongoing detox and immune modulation with minimal debris; (4) Sustained therapeutic effect from biophoton exposure.

Importantly, these features align with the cumulative benefits observed since baseline, confirming the long-term systemic improvement in blood quality and internal homeostasis in the patient receiving biophoton therapy.

Day 27 (2025.07.02) Observation is shown in Figure 6.



Figure 6: Live Blood Image taken on Day 27 Post Biophoton Therapy

Live Blood Microscopy Evaluation - Day 27 Post-Biophoton Therapy (AD Patient)

1. Excellent RBC Shape and Uniformity

- **Observation:** Red blood cells (RBCs) exhibit nearly perfect morphology: uniformly round, biconcave with clear central pallor, and no signs of crenation or distortion.
- **Interpretation:** This reflects a highly optimized red cell membrane state, suggesting long-term oxidative stress reduction, improved metabolic equilibrium, and sustained mitochondrial function - all critical for reversing or slowing Alzheimer's progression.

2. Minimal Aggregation, Ideal Dispersion

- **Observation:** RBCs are well spaced with minimal clustering. No rouleaux, clumping, or pathological patterns are visible.
- **Interpretation:** This is consistent with excellent blood fluidity and strong zeta potential, which enhances capillary flow and oxygen delivery - supporting healthy neurovascular dynamics.

3. Crystal-Clear Plasma Background

- **Observation:** The plasma is exceptionally clear, with almost no particulate matter, protein strands, or immune debris.
- **Interpretation:** This indicates very low systemic inflammation, excellent detoxification, and reduced immune burden - a stable, anti-inflammatory blood environment conducive to cognitive preservation.

4. Cellular Vitality Indicators

- **Observation:** The overall brightness and biophotonic glow of the cells is enhanced, with minimal evidence of oxidative haze or necrotic fragments.
- **Interpretation:** This suggests strong bioenergetic vitality and a restored state of cellular coherence - pointing toward an internal healing and regulatory state, as theorized in biophoton medicine.

Summary (Day 27 Post-Biophoton Therapy)

This Final Timepoint Reveals

- Peak physiological blood condition across all markers
- Sustained reversal of baseline pathological findings
- Detoxified, non-inflammatory, oxygen-rich systemic state
- Cellular bioenergetic optimization, aligning with biophotonic therapeutic goals

In sum, this image reflects a systemically rejuvenated blood profile that is not only disease-free but functionally optimized - a remarkable transformation from the pathological baseline image. This may correlate with meaningful improvements in energy, cognition, and systemic regulation in the Alzheimer's patient.

Below are Live Blood Analysis Timeline Annotations

- **Day 0:** Rouleaux formation, oxidative stress, inflammatory plasma
- **Day 3:** Reduced rouleaux, improved red blood cell (RBC) shape, clearer plasma
- **Day 5:** Optimal RBC morphology, minimal debris, strong flow dynamics
- **Day 13:** Stable clean plasma, physiological RBC spacing
- **Day 18:** Sustained vitality, minor detox signs, bioenergetic improvement
- **Day 27:** Peak blood quality - no inflammation, optimized oxygenation and circulation

Discussion

This case study presents compelling observational evidence that the application of strong biophoton generators can meaningfully improve blood fluidity and related physiological markers in a patient with early-stage Alzheimer's disease (AD). The sequential blood analyses revealed marked improvements in cellular morphology, decreased viscosity, increased oxygen saturation, and enhanced systemic homeostasis over a 4-week treatment period. These outcomes have significant clinical relevance, as cerebral microcirculation and blood-based biomarkers are increasingly implicated in both the progression and treatment response of Alzheimer's disease with biophoton generators [7, 8].

Impaired cerebral perfusion and systemic microvascular dysfunction have long been implicated in the pathogenesis of

Alzheimer's disease [3]. Torre argued that AD may in fact be a "vascular disorder with neurodegenerative consequences," citing evidence of reduced cerebral blood flow and endothelial dysfunction. Similarly, Humpel highlighted the role of chronic mild cerebrovascular insufficiency in promoting amyloid-beta deposition and oxidative damage [1]. The patient in this study presented with poor baseline blood quality - evidenced by high viscosity, low oxygenation, and visible cellular clumping - supporting this vascular hypothesis.

Alzheimer's disease is traditionally characterized by neurofibrillary tangles and β-amyloid plaques, but vascular contributions to cognitive impairment are now well-documented. Chronic cerebral hypoperfusion, endothelial dysfunction, and erythrocyte aggregation are common in AD and contribute to neuronal injury and impaired clearance of metabolic waste [3,4]. The observed reversal of rouleaux formation and improvement in cellular independence suggest enhanced zeta potential, resulting in reduced red blood cell (RBC) aggregation and improved microvascular flow - hallmarks of enhanced hemorheological health [9].

Following biophoton exposure, blood characteristics improved rapidly, particularly by Day 3, where decreased rouleaux formation and increased erythrocyte separation suggested enhanced zeta potential and lowered aggregation tendencies. These observations are consistent with findings by Pretorius et al. who demonstrated that abnormal fibrin networks and erythrocyte morphology play a central role in chronic inflammatory diseases, including neurodegenerative conditions [9]. Improvements in oxygenation and immune modulation by Day 5 and beyond may also reflect restored endothelial nitric oxide (NO) bioavailability - a known marker of vascular health and brain perfusion [4].

Biophoton fields, as delivered by the Tesla BioHealing generators, may modulate mitochondrial bioenergetics and membrane dynamics via coherent light emission in the ultraweak photon range. Prior experimental models have shown that biophoton stimulation can normalize oxidative stress markers, enhance nitric oxide (NO) production, and regulate ATP synthesis [10,11]. In this case, the progressive increase in blood oxygenation and the stabilization of systemic inflammation, as reflected by improved morphology and symptom reduction, support the hypothesis that biophoton therapy may facilitate endothelial recovery and mitochondrial recalibration. The patient's improved sleep and reduced pain without hormonal or pharmacologic aid underscore the systemic nature of these benefits, potentially linked to better autonomic regulation, similar to what we reported for using biophoton generators to successfully treated Parkinson's disease [12-14].

From a therapeutic standpoint, enhancing blood fluidity may serve as a vital adjunct to standard neuroprotective interventions. Emerging data have correlated high fibrinogen levels and microvascular thrombosis with cognitive decline and greater amyloid burden in the AD brain [15, 16]. By reducing cellular aggregation and potentially modulating the coagulation-inflammation axis, biophoton therapy may offer a vascular-centric strategy for stabilizing or even reversing cognitive symptoms in select patients. Though preliminary, the findings warrant controlled clinical trials with larger sample sizes and integrated neuroimaging and electrophysiological endpoints to validate and expand on these outcomes.

Biophoton quantum medicine presents a promising non-invasive approach to addressing neurodegenerative diseases by targeting the vascular and systemic contributors now recognized as pivotal in disease progression. This study highlights the therapeutic potential of biophoton therapy as a novel modality that may enhance cerebral blood flow, optimize mitochondrial function, and reduce neuroinflammation - factors increasingly implicated in the early stages of conditions such as AD. By restoring cellular energy balance and improving microvascular health, biophoton exposure could slow or even reverse some of the early pathological processes, offering a critical intervention point before irreversible cognitive decline sets in.

Importantly, this approach is particularly well-suited for patients in the early stages of neurodegeneration who may not qualify for pharmacological treatments due to age, comorbidities, or the lack of approved drugs for prodromal stages. Biophoton quantum medicine bridges this therapeutic gap by offering a gentle, safe, and system-wide method of support. Its potential to improve systemic vascular function aligns with emerging research that identifies vascular insufficiency as a key contributor to neurodegenerative decline. As such, biophoton therapy may redefine the standard of care for early intervention, transforming into how neurodegenerative diseases are managed and offering hope for delaying or mitigating their progression.

Conclusion

This case study provides preliminary yet meaningful evidence that strong biophoton field exposure may enhance blood fluidity, cellular morphology, and systemic physiological function in a patient with early-stage Alzheimer's disease. Improvements in blood viscosity, oxygen saturation, and cellular dispersion were accompanied by reduced systemic pain, better sleep quality, and metabolic stabilization all without pharmacologic adjustments. These findings support the hypothesis that vascular and microcirculatory optimization may play a key role in neurodegenerative disease management.

While limited by the single-subject design, the consistent improvements observed over multiple time points warrant further investigation in controlled, multi-patient studies. Future research should integrate neurocognitive assessments, cerebral perfusion imaging, and inflammatory biomarker analysis to elucidate the mechanisms of biophoton therapy and validate its clinical utility. If substantiated in broader trials, biophoton therapy could emerge as a novel non-invasive adjunct for early intervention in Alzheimer's disease addressing not only brain function but also the vascular terrain upon which cognition depends.

References

1. Humpel C (2011) Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?. Experimental Gerontology 46: 225232.
2. Wang R, Zhang D, Chan P (2016) Blood-brain barrier dysfunction in Alzheimer's disease. Neuropsychiatric Disease and Treatment 12: 2109-2119.
3. de la Torre JC (2002) Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 33: 1152-1162.
4. Cortes Canteli M, Iadecola C (2020) Alzheimer's disease and vascular aging: JACC focus seminar. Journal of the American College of Cardiology 75: 942-951.
5. Pretorius E, Page MJ, Engelbrecht L, Ellis GC, Kell DB (2018) Substantial fibrin amyloid formation in type 2 diabetes assessed using amyloid-selective fluorescent stains. Scientific Reports 8: 16734.
6. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathologica 118: 103-113.

7. Liu JZ, Gu HY, Smotrys MA, Robinson SD (2024) Alzheimer's Disease Was Successfully Treated with Biophoton Generators. The Alzheimer's Association International Conference (AAIC), July 27-Aug 2, 2024, Philadelphia https://aaic.alz.org/highlights2024.asp.
8. James Z Liu, Mariola A Smotrys, Seth D Robinson, Hui X Yu, Sherry X Liu, et al. (2025) Quantitative EEG Evidence of Cognitive Restoration in Alzheimer's Disease Following Biophoton Generator Therapy. Journal of Neurology Research Reviews & Reports 7: 1-10.
9. Hu Y, Gu HY, Liu JZ (2025) Reversal of Tissue Glycation and Cholesterol Accumulation by Strong Biophotons: A New Anti-Aging Mechanism. Gerontol & Geriatric Stud 9: 000715.
10. Popp FA (2003) Properties of biophotons and their theoretical implications. Indian Journal of Experimental Biology 41: 391-402.
11. van Wijk R, van Wijk EPA, Bajpai RP (2008) Ultraweak photon emission and the matrix of life. BioSystems 92: 316-323.
12. Hu Y, Gu HY, Liu JZ (2025) Twelve-Day Live Blood Analysis Reveals Hemorheological and Microvascular Restoration in a Parkinsons Disease Patient Following Biophoton Therapy. Journal of Neurology Research Reviews & Reports 7: 1-6.
13. Liu JZ, Smotrys MA, Robinson SD, Liu SX, Gu HY (2025) Therapeutic Benefits of Biophoton Therapy in Parkinson's Disease: Clinical Evidence from a Pilot and Real-World Study. Journal of Neurology Research Reviews Reports 7: 1-6.
14. Liu JZ, Gu HY, Hu Y, Smotrys M, Robinson S (2025) Safety and Efficacy of Biophoton Quantum Medicine in the Treatment of Neurodegenerative Diseases. Journal of Neurology Research Reviews & Reports 7: 1-6.
15. Ahn HJ, Glickman JF, Poon KL, Zamolodchikov D, Jno Charles OC, et al. (2010) A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. Journal of Experimental Medicine 207: 2703-2719.
16. Zamolodchikov D, Chen ZL, Serfling R, Strickland S (2016) Abnormalities in fibrin structure and function promote microvascular thrombosis in Alzheimer's disease. Brain Research 1635: 126-134.